Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.

Ghafuri DL, Chaturvedi S, Rodeghier M, Stimpson SJ, McClain B, Byrd J, DeBaun MR
Pediatr Blood Cancer. 2017 64 (7)

PMID: 28035747 · DOI:10.1002/pbc.26401

In a retrospective cohort study, we tested the hypothesis that when prescribing hydroxyurea (HU) to children with sickle cell anemia (SCA) to prevent vaso-occlusive events, there will be a secondary benefit of maintaining low transcranial Doppler (TCD) velocity, measured by imaging technique (TCDi). HU was prescribed for 90.9% (110 of 120) of children with SCA ≥5 years of age and followed for a median of 4.4 years, with 70% (n = 77) receiving at least one TCDi evaluation after starting HU. No child prescribed HU had a conditional or abnormal TCDi measurement. HU initiation for disease severity prevention decreases the prevalence of abnormal TCDi velocities.

© 2016 Wiley Periodicals, Inc.

MeSH Terms (14)

Adolescent Anemia, Sickle Cell Antisickling Agents Blood Flow Velocity Cerebrovascular Circulation Child Child, Preschool Cohort Studies Female Humans Hydroxyurea Male Retrospective Studies Ultrasonography, Doppler, Transcranial

Connections (2)

This publication is referenced by other Labnodes entities:

Links